Histone Modifications

Introduction

Histone Modifications is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Histone modifications are post-translational chemical alterations to histone proteins that regulate chromatin structure and gene expression without changing the DNA sequence. These epigenetic modifications - including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation - control the accessibility of DNA to transcriptional machinery and play fundamental roles in neuronal gene expression, synaptic plasticity, and memory formation. In neurodegenerative diseases, widespread dysregulation of histone modifications contributes to aberrant gene expression programs that promote neuroinflammation, synaptic loss, and neuronal death (Nativio et al., 2020). ^{1An epigenetic blockade of cognitive functions in the neurodegenerating brain. *Nature*. 2012;483(7388):222-226. DOI2012 · DOI 10.1038/nature10860Open reference}

Histone deacetylase (HDAC inhibitors have emerged as promising therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and ALS, with several compounds advancing through preclinical and clinical development (Shukla & Singh, 2024). ^{2Shukla S, Singh SS. Restoring the epigenome in Alzheimer''s Disease: advancing HDAC inhibitors as therapeutic agents. *Drug Discov Today*. 2024;29(8):104056. PMID: 388305012024 · PMID 38830501Open reference}

Histone Biology

Nucleosome Structure

DNA in the nucleus is packaged around histone octamers to form nucleosomes, the fundamental units of chromatin: ^{3HDAC2 negatively regulates memory formation and synaptic plasticity. *Nature*. 2009;459(7243):55-60. DOI2009 · DOI 10.1038/nature07925Open reference}

• Core histones: Two copies each of H2A, H2B, H3, and H4 form the octamer

• DNA wrapping: ~147 bp of DNA wraps ~1.65 turns around each octamer

• Linker histone: H1 binds linker DNA between nucleosomes, compacting higher-order chromatin structure

• Histone tails: N-terminal tails protrude from the nucleosome and are the primary targets for post-translational modifications

The Histone Code

The “histone code hypothesis” proposes that specific combinations of histone modifications create a code read by effector proteins to regulate gene expression: ^{4Altered histone acetylation is associated with age-dependent memory impairment in mice. *Science*. 2010;328(5979):753-756. DOI2010 · DOI 10.1126/science.1186088Open reference}

• Euchromatin (open, transcriptionally active): Associated with acetylation, H3K4me3, H3K36me3

• Heterochromatin (closed, transcriptionally silent): Associated with deacetylation, H3K9me3, H3K27me3

• Bivalent domains: Carry both activating (H3K4me3) and repressive (H3K27me3) marks; “poised” for rapid activation or silencing

Major Types of Histone Modifications

Acetylation

The most studied histone modification in neurodegeneration: ^{5Konsoula Z, Bhatt AB. Epigenetics in neurodegenerative diseases. *Biomolecules*. 2024;16(1):103. DOI2024 · DOI 10.3390/biom16010103Open reference}

Mechanism: ^{6The role of histone modifications: from neurodevelopment to neurodiseases. *Signal Transduct Target Ther*. 2022;7(1):217. DOI2022 · DOI 10.1038/s41392-022-01078-9Open reference}

• Addition of acetyl groups to lysine residues on histone tails

• Writers: Histone acetyltransferases (HATs) - CBP/p300, PCAF, GCN5, Tip60

• Erasers: Histone deacetylases (HDACs) - 18 mammalian HDACs in 4 classes

• Readers: Bromodomain-containing proteins (BRD2, BRD4)

Effect: Neutralizes the positive charge on lysine, weakening histone-DNA interactions and opening chromatin for transcription. ^{7Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer's Disease. *Neurobiol Learn Mem*. 2011;96(1):19-26. DOI2011 · DOI 10.1016/j.nlm.2011.04.002Open reference}

Key acetylation marks in the brain: ^{8Recovery of learning and memory is associated with chromatin remodelling. *Nature*. 2007;447(7141):178-182. DOI2007 · DOI 10.1038/nature05772Open reference}

| Mark | Location | Function | Change in AD | ^{9Multiple roles of HDAC inhibition in neurodegenerative conditions. *Trends Neurosci*. 2009;32(11):591-601. DOI2009 · DOI 10.1016/j.tins.2009.06.002Open reference} |------|----------|----------|-------------| ^{10Tau promotes neurodegeneration through global chromatin relaxation. *Nat Neurosci*. 2014;17(3):357-366. DOI2014 · DOI 10.1038/nn.3639Open reference} | H3K9ac | Promoters | Gene activation | Globally decreased | ^{2Shukla S, Singh SS. Restoring the epigenome in Alzheimer''s Disease: advancing HDAC inhibitors as therapeutic agents. *Drug Discov Today*. 2024;29(8):104056. PMID: 388305012024 · PMID 38830501Open reference}0 | H3K14ac | Promoters | Gene activation | Decreased | | H3K27ac | Enhancers, promoters | Active enhancer mark | Redistributed | | H4K16ac | Gene bodies | Transcription elongation | Decreased | | H4K12ac | Promoters | Memory-related gene expression | Decreased with aging |

Methylation

Mechanism:

• Addition of methyl groups to lysine or arginine residues

• Writers: Histone methyltransferases (HMTs) - SET-domain proteins (EZH2, G9a, SUV39H1), DOT1L

• Erasers: Histone demethylases (HDMs) - LSD1, JMJD family

• Readers: Chromodomain, Tudor domain, PHD finger proteins

• Can be mono-, di-, or trimethylated (each with distinct functions)

Key methylation marks:

• H3K4me3: Activating mark at promoters; decreased at memory genes in AD

• H3K9me2/3: Repressive mark; increased at neuroprotective genes in AD

• H3K27me3: Polycomb-mediated silencing; altered in neurodegeneration

• H3K36me3: Transcription elongation; mark of actively transcribed genes

• H4K20me3: Constitutive heterochromatin; involved in DNA damage response

Phosphorylation

• Addition of phosphate groups to serine, threonine, or tyrosine residues

• H3S10ph: Associated with mitotic chromosome condensation and immediate-early gene activation

• gamma-H2AX (H2AXS139ph): DNA double-strand break marker; increased in AD and ALS neurons, indicating elevated DNA damage

• Catalyzed by kinases (Aurora B, MSK1, ATM) and removed by phosphatases

Ubiquitination

• H2AK119ub: Polycomb-mediated transcriptional repression (PRC1 complex)

• H2BK120ub: Required for H3K4 and H3K79 methylation; facilitates transcription

• Altered in Huntington’s disease due to mutant huntingtin interactions with the ubiquitin-proteasome system

Histone Modifications in Alzheimer’s Disease

Global Epigenomic Changes

Large-scale chromatin profiling studies have revealed widespread histone modification changes in AD brains:

• H3K27ac redistribution: Nativio et al. (2020) performed genome-wide H3K27ac profiling in AD brains and found massive redistribution rather than simple loss - enhancers at immune/inflammatory genes gain acetylation while neuronal/synaptic gene enhancers lose acetylation (Nativio et al., 2020)

• H3K9ac loss: Global decrease in H3K9 acetylation at promoters of synaptic plasticity and memory genes

• H4K16ac reduction: Associated with chromatin compaction and gene silencing in AD

• H3K4me3 changes: Altered at promoters of tau]-related and inflammatory genes

Mechanisms Driving Epigenetic Dysregulation

1. HDAC upregulation: Several HDACs (HDAC2, HDAC3, HDAC6) are elevated in AD brains

2. HAT loss: CBP/p300 activity decreases with amyloid-beta and tau] pathology

3. Oxidative modification: reactive oxygen species directly modify histones and epigenetic enzymes

4. Tau-mediated heterochromatin loss: Tau interacts with heterochromatin and its loss leads to aberrant gene expression, including retrotransposon activation

5. Inflammatory signaling: NF-κB activation recruits HATs to inflammatory gene promoters while HDACs are redirected from neuronal genes

Specific HDAC Roles in AD

• HDAC2: Upregulated in AD hippocampal neurons; negatively regulates memory gene expression; its knockdown restores synaptic plasticity and memory in AD mice (Graff et al., 2012)

• HDAC3: Negative regulator of memory consolidation; elevated in AD

• HDAC6: Deacetylates tau] and alpha-tubulin; promotes tau aggregation; inhibition reduces tau pathology

• SIRT1 (Class III [HDAC: Neuroprotective; decreases in AD brains; activates alpha

Histone Modifications in Other Neurodegenerative Diseases

Parkinson’s Disease

• alpha-synuclein directly binds histones and inhibits histone acetylation

• Nuclear alpha-synuclein sequesters HATs, reducing global acetylation

• HDAC inhibitors protect dopaminergic neurons in MPTP and alpha-synuclein PD models

• H3K27me3 changes at PD risk gene loci (SNCA, LRRK2, GBA)

Huntington’s Disease

• Mutant huntingtin sequesters CBP/p300 (HAT) in aggregates, causing global hypoacetylation

• HDAC inhibitors (SAHA, sodium butyrate) improve motor and cognitive phenotypes in HD mice

• H3K4me3 is reduced at neuronal identity genes in HD striatum

• HD is the neurodegenerative disease with the strongest evidence for epigenetic therapies

ALS

• TDP-43 and FUS interact with histone-modifying complexes

• Increased H2AX phosphorylation (gamma-H2AX) indicates DNA damage in motor neurons

• HDAC6 inhibition improves axonal transport and motor function in ALS models

• C9orf72 repeat expansions alter chromatin structure at the repeat locus

Therapeutic Targeting

HDAC Inhibitors

HDAC inhibitors are the most advanced epigenetic therapeutic strategy for neurodegeneration:

Compound	HDAC Selectivity	Status	Key Evidence
Vorinostat (SAHA)	Pan-HDAC (I, II)	FDA-approved (cancer)	Improves memory in AD mice; restores histone acetylation
Sodium valproate	Class I/IIa	FDA-approved (epilepsy)	Clinical trials in AD; mixed results
CI-994 (Tacedinaline)	Class I selective	Preclinical (AD)	Restores hippocampal memory gene expression
Tubastatin A	HDAC6 selective	Preclinical	Reduces tau phosphorylation and aggregation
RGFP966	HDAC3 selective	Preclinical	Enhances memory consolidation
Compound 3	HDAC11 selective	Preclinical (2025)	Brain-penetrant; colocalizes with amyloid plaques

Challenges for Epigenetic Therapies

• Selectivity: Pan-HDAC inhibitors affect thousands of genes; isoform-selective inhibitors are preferred

• Cell-type specificity: Different cell types require different epigenetic programs; systemic HDAC inhibition may be harmful

• BBB penetration: Many HDAC inhibitors have poor blood-brain barrier permeability

• Side effects: Hematological toxicity, GI effects, fatigue

• Dosing: Therapeutic window between efficacy and toxicity is narrow

• Irreversibility concerns: Some epigenetic changes may be difficult to reverse once established

Emerging Approaches

• BET bromodomain inhibitors: Block readers of acetylated histones; reduce inflammatory gene expression

• EZH2 inhibitors: Target H3K27me3 writer; may reactivate silenced neuroprotective genes

• LSD1 inhibitors: Block histone demethylase; restore H3K4me at memory genes

• CRISPR-based epigenetic editing: Targeted modification of histone marks at specific genomic loci (experimental)

• Dual-target inhibitors: Compounds targeting both RIPK1 and HDACs for combined anti-inflammatory and epigenetic effects (2024-2025 development)

External Links

• PubMed — Biomedical literature database

• ENCODE Project — Encyclopedia of DNA Elements

• Allen Brain Atlas — Brain gene expression data

Brain Atlas Resources

• Allen Human Brain Atlas: Histone Modifications expression search

• Allen Mouse Brain Atlas: Histone Modifications search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Histone Modifications developmental expression

See Also

• dopaminergic neurons

• motor neurons

• Alzheimer’s Disease

• Amyloid-Beta Aggregation

• Tau Pathology

• Parkinson’s Disease

• ALS

• Huntington’s Disease

• neuroinflammation

• Synaptic Dysfunction

Background

The study of Histone Modifications has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.